Deutsche Bank raised the firm’s price target on Agilon Health to $28 from $26 and keeps a Buy rating on the shares. The company ended 2022 with another solid quarter, reporting a strong sales beat, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGL: